Drug Profile
MP 196
Alternative Names: Anti IL23/P19 monoclonal antibody - OSE Immunotherapeutics; MP-196Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Effimune
- Developer OSE Immunotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Autoimmune disorders in France (Parenteral) (OSE Immunotherapeutics pipeline; August 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (Parenteral)
- 31 May 2016 Effimune has merged with OSE Pharma to form OSE Immunotherapeutics